Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Takes Unapproved Quinine Drugs Off The Market

This article was originally published in The Pink Sheet Daily

Executive Summary

Physicians warned against prescribing for leg cramps, which accounts for 70% of usage.

You may also be interested in...

Mutual Launches Malaria Drug Qualaquin, Warns Of Unapproved Competitors

Company hopes to get FDA to remove other quinine products from the market.

FDA Kicks Off Unapproved Drug Crack-Down With Carbinoxamine Enforcement

FDA is focusing initially on drugs containing the antihistamine carbinoxamine because of safety concerns in children.

Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says

Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts